Skip to content Skip to footer
Join our LinkedIn Group and be part of the conversation on AI in life sciences Subscribe to our YouTube channel for the latest MadeAi product updates
Login
Login
Close

Meghan Oates-Zalesky 

Meghan Oates‑Zalesky is Chief Marketing Officer at CapeStart and MadeAi, with over 20 years of experience in healthcare technology and life sciences. Previously CMO at Apollo Intelligence, she helped grow the company from a small startup into a global enterprise. A PharmaVOICE Woman of Influence (2021), Meg’s thought leadership has appeared in leading industry publications. She holds degrees from Harvard and the London School of Economics and is a published novelist and avid equestrian.

112 articles published Follow:
roche

From Explainable AI Screening to Publication-Grade Evidence for Roche HEOR Team

Case StudyApril 7, 2026226Views0Likes0Comments
How do you screen thousands of abstracts with transparency and reproducibility using minimal training data? In this case study, MadeAi partnered with the Roche HEOR team to design and validate an explainable AI pipeline for title and abstract screening in a systematic literature review. Using a structured PICO-based framework, the team screened over 3,300 abstracts…

Read More

Agentic AI Driving the Next Phase of Continuous Evidence Generation in Pharma

2026 Prediction #4: Agentic AI Driving the Next Phase of Continuous Evidence Generation in Pharma

BlogMarch 31, 2026188Views0Likes0Comments
For years, the pharmaceutical industry has followed a familiar evidence cycle. Teams design a clinical trial, execute it, lock the database, analyze the results, and wait for another study to address remaining questions. They wait for post-market surveillance to reveal real-world outcomes and for regulators or payers to request additional data before reimbursement decisions. However,…

Read More

MadeAi | 2026 Prediction #3: Role-Based Tool Isolation: The Gold Standard for Secure Pharma AI

2026 Prediction #3: Role-Based Tool Isolation: The Gold Standard for Secure Pharma AI

BlogMarch 25, 2026148Views0Likes0Comments
The pharmaceutical industry is currently at a pivotal moment in the AI landscape. After years of cautious AI experimentation limited to isolated labs and pilot programs, something fundamentally different is unfolding in 2026. The central question has shifted from “Does AI work?” to “How do we deploy it safely and at scale?” especially in organizations…

Read More